Showing 6551-6560 of 7113 results for "".
- DERMAFLASH® Brings Benefits of Dermaplaning Homehttps://practicaldermatology.com/news/dermaflash-brings-benefits-of-dermaplaning-home/2458738/DERMAFLASH™ is the newest addition to the DIY beauty device market. Designed specifically for women, the noninvasive exfoliation device is based on the principles of dermaplaning. DERMAFLASH uses sonic vibration to sweep away dead skin cells, vellus and even coarser
- Review Article Shines Spotlight on Neurocutaneous Disordershttps://practicaldermatology.com/news/review-article-shines-spotlight-on-neurocutaneous-disorders/2458739/There are at least 60 genetic neurocutaneous disorders that involve the skin, central nervous system, according to a review article in the Current Neurology and Neuroscience Reports. For example, neurofibrom
- FDA Approves Updated Label for New Dosing Regimen for Allergan's Dalvancehttps://practicaldermatology.com/news/fda-approves-updated-label-for-new-dosing-regimen-for-allergans-dalvance/2458741/The FDA has approved Allergan plc’s supplemental new drug application (sNDA) to update the label for Dalvance® (dalbavancin) for injection. The expanded label will include a single dose administered as a 30-minute intravenous (IV) infusion of Dalvance for the treatment o
- Indoor Tanning Linked to Teen Substance Abusehttps://practicaldermatology.com/news/indoor-tanning-linked-to-teen-substance-abuse/2458742/New research links teen indoor tanning with substance abuse. In a study of Colorado high school students, teens who took steroids were among the most likely to use tanning beds, especially adolescent boys. Alcohol consumption in the past 30 days, marijuana use and lifetime use of select i
- Aclaris Therapeutics Initiates Phase 3 Clinical Trials of A-101 for the Treatment of Seborrheic Keratosishttps://practicaldermatology.com/news/aclaris-therapeutics-initiates-phase-3-clinical-trials-of-a-101-for-the-treatment-of-seborrheic-keratosis/2458748/Aclaris Therapeutics, Inc. initiated two Phase 3 clinical trials to evaluate A-101 Topical Solution for the treatment of seborrheic keratosis (SK). The two Phase 3 clinical trials will evaluate the safety and efficacy of A-101 Topical Solution comp
- New World Market for Prescription Dermatological Drugs Report Releasedhttps://practicaldermatology.com/news/new-world-market-for-prescription-dermatological-drugs-report/2458749/Research and Markets recently added the "World Market for Prescription Dermatological Drugs, 9th Edition (Anti-acne, Anti-aging, Dermatitis, Hair Loss, Psoriasis, Skin Cancer,Melasma and Seborrhea Treatments)&qu
- Advancing Age May Affect Psoriasis Patients' Access to Biologicshttps://practicaldermatology.com/news/advancing-age-may-affect-psoriasis-patients-access-to-biologics/2458746/Elderly psoriasis patients may be less likely to receive biologics, according to a new study out of Umeå University in Sweden. Specifically, an age increase of 30 years resulted in an average 65 percent reduction in likelihood of obtaining treatment with biologics in this population
- ASDS Announces President's Award Recipientshttps://practicaldermatology.com/news/asds-announces-presidents-award-recipients/2458752/The American Society for Dermatologic Surgery honored four of its members with a President’s Award for contributing to the Society or the medical specialty in an extraordinary or unique way. George J. Hruza, MD, MBA, presented the awards in his final d
- Study Highlights Risk Factors for cSCC Recurrence, Metastasis and Deathhttps://practicaldermatology.com/news/study-highlights-risk-factors-for-cscc-recurrence-metastasis-and-death/2458753/Tumor depth confers the highest risk of local recurrence and metastasis of cutaneous squamous cell carcinoma (cSCC) and tumor diameter exceeding 20 mm is associated with the highest risk for disease-specific death, a new study suggests. The findings are published online in
- Study: With Botox 'Chemodenervation,' Dermal Fillers Last Longerhttps://practicaldermatology.com/news/study-with-botox-chemodenervation-dermal-fillers-last-longer/2458757/Experimental evidence supports a simple technique for prolonging the effects of Hyaluronic acid (HA) dermal fillers: using them together with botulinum toxin, according to a study published in the January issue of Plastic and